──New Patient Data Further
Implicates CCL24 in Fibrotic Disease Pathology and Prognosis
and
Supports Rationale for the Role of Chemomab's CCL24-Neutralizing
Antibody CM-101
in Systemic Sclerosis and Other Fibro-inflammatory
Diseases──
MILAN and TEL AVIV,
Israel, June 2, 2023 /PRNewswire/ -- Chemomab
Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage
biotechnology company focused on the discovery and development of
innovative therapeutics for fibro-inflammatory diseases with high
unmet need, today announced a poster presentation at the 2023
European Congress of Rheumatology, hosted by the European Alliance
of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.
The poster, "CCL24 serum concentration predicts both vascular
and fibrotic complications in systemic sclerosis," was
presented today by Professor Enrico De
Lorenzis of the Leeds Institute of Rheumatic and
Musculoskeletal Diseases at the University of Leeds in the UK. The
study was conducted by Professor De Lorenzis and his colleagues who
enrolled systemic sclerosis (SSc) patients from an observational
cohort and compared them with age- and gender-matched controls.
Results from the study demonstrate that high serum concentration
levels of the pro- fibrotic and pro-inflammatory cytokine CCL24
were correlated with SSc severity, including higher incidence of
several measurable fibrosis-associated symptoms, a three-fold
increased risk of interstitial lung disease (ILD) progression and a
shorter 5-year SSc-related survival time.1
Professor De Lorenzis noted, "These new data add to previous
observations of elevated CCL24 levels in SSc patients and reinforce
the therapeutic rationale supporting inhibition of CCL24 as a
potentially effective treatment for SSc and other fibrotic
conditions."
"These results are consistent with the findings of our previous
studies in SSc preclinical models and patient samples showing that
higher CCL24 levels reflect more severe disease and can predict its
prognosis," said Adi Mor, PhD,
co-founder and Chief Scientific Officer of Chemomab, and a
co-author of the poster. "They reinforce the therapeutic rationale
for the potential clinical utility of CM-101, our first-in-class
anti-CCL24 antibody that aims to break the fibro-inflammatory
vicious cycle we believe is central to the pathophysiology of SSc,
primary sclerosing cholangitis and other fibrotic diseases."
1 - CCL24 serum concentration predicts both vascular and
fibrotic complications in systemic sclerosis, Enrico De Lorenzis, Adi
Mor, Rebecca Ross,
Stefano Di Donato, Revital Aricha, Hilit
Levi, Ilan Vaknin, Francesco
Del Galdo
A copy of the poster will be available at the R&D
portion of Chemomab's website.
For more information on the EULAR Congress,
visit https://congress.eular.org/
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company discovering and developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the chemokine CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies to date, CM-101 appears safe, with
the potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has reported encouraging
results from a Phase 2 liver fibrosis study in NASH patients and an
investigator study in patients with severe lung injury. A Phase 2
trial in primary sclerosing cholangitis patients is ongoing. For
more information on Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These forward-looking statements
include, among other things, statements regarding the clinical
development pathway for CM-101; the future operations of Chemomab
and its ability to successfully initiate and complete clinical
trials and achieve regulatory milestones; the nature, strategy and
focus of Chemomab; the development and commercial potential and
potential benefits of any product candidates of Chemomab; and that
the product candidates have the potential to address high unmet
needs of patients with serious fibrosis-related diseases and
conditions. Any statements contained in this communication that are
not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Chemomab's current expectations. Forward-looking
statements involve risks and uncertainties. Because such statements
deal with future events and are based on Chemomab's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Chemomab could
differ materially from those described in or implied by the
statements in this presentation, including those found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except as required by law.
Contacts:
Investors:
|
Investors & Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations
|
ir@chemomab.com
|
Strategic
Communications
|
|
Phone: +1 (917)
355-9234
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/patient-data-presented-at-2023-eular-congress-highlights-how-serum-ccl24-levels-can-predict-vascular-and-fibrotic-complications-of-systemic-sclerosis-301841048.html
SOURCE Chemomab Therapeutics, Ltd.